Droia invests in promising new cancer therapies, and accelerates their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programs. Droia has an in-house team of drug development professionals who accompany the programs closely and provide hands-on support. Droia invests in early financing rounds and also incubates new companies. Since cancer is a global disease and cancer research a global endeavour, Droia invests globally.
Alychlo invested in the first two Droia funds and co-invested directly alongside Droia in Tusk Therapeutics.
For more information: www.droiaventures.com